Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7103MR)

This product GTTS-WQ7103MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7103MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1314MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ5198MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ2188MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ7799MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ15496MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ4756MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ14366MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ3127MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW